



The Cardiac Intensive Care Unit Survival Guide



Created by

Peter Haigh





How to use this powerpoint

- “Control F” (find) a topic
- Review slides and check out links to other lectures, videos, resources, etc.
- Ask your fellow or attending to expand on topics
- Don’t forget to review the CCU orientation document for the ‘nuts and bolts’ of the CCU

Table of Contents

Hemodynamics and Shock

Normal Intracardiac Pressures

- RA 0-5
- RV 25/5
- PA 25/10
- LA 10-15
- LV 120/5-10
- Aorta 120/80

"Quarter (RV=25), Nickel (RA=5), Dime (LA=10)"



Measuring Intracardiac Pressures

- A pulmonary artery catheter (Swan-Ganz) is inserted through a vein (usually the jugular)
- Terminates in the PA
- Used to measure pressures and calculate cardiac output (more on this later)



Swan-Ganz Catheter



- Multiple ports that terminates at different points along the catheter
- At the end of the catheter is a balloon which can be inflated or deflated

Normal Swan Pressure Waveforms



- As the Swan is advanced, we can observe the pressure waveform in the cardiac chambers
- To get the “wedge” pressure, the catheter must be in a pulmonary artery and the balloon is inflated

Estimating Left Atrial (LA) Pressure

- When the balloon is inflated, the pulmonary vessel is occluded and there is no flow from the PA / right heart reaching the distal pressure transducer
- The pressure transducer distal to the balloon “feels” the pressure in the LA, this is called the pulmonary capillary wedge pressure (PCWP)
- The PCWP = the LA pressure



PA Catheters General Principles

- Routine use is not recommended, and in fact is associated with increased mortality.
- However when used in carefully selected patients, it is an invaluable tool in the CCU. (improved mortality in observational studies with odds ratio for mortality around 0.7)
- Uses:
  - Determine hemodynamics in undifferentiated shock (when other methods of determined shock type have been inconclusive)
  - To guide management in severe cardiogenic shock or complex mixed shock

Swan Positioning



- Swan tip should terminate in the proximal right or left PA, ideally within the mediastinal shadow
- The waveform should demonstrate a typical PA pressure tracing (with balloon deflated)
- If waveform shows a PCWP tracing, it is too deep and should be retracted
- Never let the swan rest within the RV → risk of VT
- Always get a repeat CXR after Swan repositioning

PA Catheters Cautions

- If you are not using the Swan, it should be removed (just like for any central line)
- Complications: pulmonary infarct, arrhythmias (heart block, VT), infection, balloon rupture
- Extreme caution in patients with LBBB – During insertion, can damage the right bundle causing complete heart block if preexisting LBBB.
- Monitoring:
  - Determine frequency of “Swan numbers” – q8 hours at least
  - Some suggest a daily CXR to monitor position
- Nurses do not “wedge” the Swan (inflate the balloon to obtain the PCWP), ask your attending or fellow to do this

Using a Swan for cardiac output

- A blood sample can be collected from the main PA artery to find the Mixed Venous blood oxygen saturation (MVO2)
- The MVO2 can be used to calculate cardiac output (more on this later)
- The cardiac output can also be calculated using the Thermodilution method. This is rarely done outside of the cath lab
- Once the cardiac output and intracardiac pressures are known, other hemodynamic indices can be calculated

The Fick Equation

$$\text{cardiac output} = \frac{O_2 \text{ consumption}}{[O_2]_{\text{arterial}} - [O_2]_{\text{pulmonary artery}}}$$

CO = Oxygen consumption / Oxygen difference

- Numerator: O2 Consumption = Body Surface Area (BSA) x 125
- Denominator: O2 difference
  - O2 arterial = O2 sat on pulse ox (or from ABG)
  - O2 pulmonary artery = MVO2 (oxygen sat after all oxygen has been extracted from the tissues)

The Fick Equation

$$\text{cardiac output} = \frac{O_2 \text{ consumption}}{[O_2]_{\text{arterial}} - [O_2]_{\text{pulmonary artery}}}$$

Numerator: BSA x 125 ml/min/m2

Denominator: Hemoglobin [g/dL] x 10 x 1.36 [ml O2 / g of Hgb] x (arterial sat – MVO2 sat)

$$\text{BSA } (m^2) = \sqrt{\frac{[\text{height (cm)} \times \text{weight (kg)}}{3600}}$$

Practice calculating a Fick cardiac output

- You admit a sick patient with suspected cardiogenic shock. He has a Swan in place. His BSA is 2 based off height and weight. Hgb is 11
- Swan data:
  - RA 20
  - RV 44/15
  - PA 44/33
  - PCWP 22
  - MVO2 48%
  - O2 sat 96%
- What's the cardiac output using the Fick Equation?

Calculate CO using Fick

- CO = O2 consumption / O2 difference
- O2 consumption = BSA x 125 = 2 x 125 = **250**
- O2 difference = Hemoglobin [g/dL] x 10 x 1.36 [ml O2 / g of Hgb] x (arterial sat – MVO2 sat)
- = 12 x 10 x 1.36 x (0.96 – 0.48) = **78**
- CO = 250 / 78 = **3.2 L/min**
- Cardiac Index = CO / BSA = 3.2 / 2 = **1.6 L/min/m2**

- BSA = 2
- Hgb 11
- RA 20
- RV 44/15
- PA 44/33
- PCWP 22
- MVO2 48%
- O2 sat 96%

Swan Calculated Values

Once Cardiac Output has been determined, other hemodynamic information can be calculated:

CI = CO / BSA

$$SVR = \frac{(MAP - \text{mean RAP}) \times 80}{CO}$$

$$PVR = \frac{\text{mean PAP} - PCWP}{CO}$$

- CI = Cardiac Index – cardiac output normalized to body size
- SVR = Systemic Vascular Resistance – measure of how much the arteries are “clamped down” or afterload
- PVR = Pulmonary Vascular Resistance – measure of how much the pulmonary vascular is “clamped down” or RV afterload
- BSA = Body Surface Area – measure of body size

Normal Hemodynamics

The “normal” range will vary depending on patient factors but in general:

Measured:

- RA 0-5
- RV 25/5
- PA 25/10
- LA (PCWP) 10-15
- LV 120/5-10
- Aorta 120/80

Calculated:

- Cardiac Output: 4 – 7 LPM
- Cardiac Index: 2.8 – 4.2 LPM/m^2
- SVR: 900 – 1,400 dynes
- PVR: 1.9 – 3.1 dynes

Shock

Shock Types

- Shock type is defined by the primary problem or cause:
  - Cardiogenic – the heart can't / won't pump blood to maintain organ perfusion
  - Distributive – peripheral vascular resistance is too low to maintain organ perfusion
  - Hypovolemia – there is not enough intravascular blood volume to maintain organ perfusion
- If shock type is uncertain, patient may benefit from a Swan to gather hemodynamic data
  - Determine shock type
  - Guide management

Shock Types

- Combine clinical picture with hemodynamic data to define shock type
- Not all patients need a Swan to determine shock type, in fact most do NOT need one

Type of shock	CO	SVR	PWP	CVP
Hypovolemic	↓	↑	↓	↓
Cardiogenic	↓	↑	↑	↑
Distributive	↑	↓↓	↓	↓

CO=Cardiac Output
PWP=Pulmonary wedge pressure
↑ = Increase; ↓ = Decrease

SVR=Systemic vascular resistance
CVP=Central venous pressure

64

Shock Types Practice - Matching

Shock Type:	Hemodynamic Profile:
1. Distributive	A. CVP 3, PCWP 8, SVR 1,900, CO 3.7 LPM
2. Hypovolemic	B. CVP 19, PCWP 24, SVR 2,200, CO 2.9 LPM
3. Cardiogenic	C. CVP 2, PCWP 9, SVR 650, CO 6.6 LPM

Shock Types Practice - Matching

Shock Type:	Hemodynamic Profile:
1. Distributive	A. CVP 3, PCWP 8, SVR 1,900, CO 3.7 LPM
2. Hypovolemic	B. CVP 19, PCWP 24, SVR 2,200, CO 2.9 LPM
3. Cardiogenic	C. CVP 2, PCWP 9, SVR 650, CO 6.6 LPM



Cardiogenic Shock

- A heterogenous multifactorial syndrome in which a cardiac disorder results in insufficient cardiac output culminating in end-organ hypoperfusion
- 30 day mortality is about 40% and 1 year mortality is 50%
- Cardiogenic shock (CGS) due to an acute MI is the most studied and best form described in the literature
- CGS due acute MI can be used to illustrate the pathophysiology, management, and treatment…

Pathophysiology:
A vicious cycle



Acute ischemic insult

↓

Decreased Cardiac Output

↓

Systemic hypoperfusion

↓

Sympathetic and neurohormonal activation (↑SVR)

↓

Worsened Cardiac Output

(due to ↑ afterload and ↑ O2 demand)

↓

↑ LVEDP → pulmonary edema

(↓O2 supply)

↓

LV dilation and worsened CO

(fall off Starling Curve)

End Organ Failure



TABLE 1 SUSPECT CS: A Mnemonic to Aid in Confirming a Diagnosis of CS

Symptoms/Signs	Altered mental status, confusion, chest pain or pressure, cold and clammy extremities, rapid pulse, low pulse pressure (<25% of SBP), elevated jugular venous pressure, crackles, rales, orthopnea, paroxysmal nocturnal dyspnea, lower extremity edema
Urine output	Oliguria or anuria, <30 mL/h (<0.5 mL/[kg·h])
Sustained hypotension	SBP <90 mm Hg, MAP <65 mm Hg for >30 min or a >30-mm Hg decrease from baseline, or the need for pharmacological or mechanical support to maintain SBP >90 mm Hg
Perfusion	Evaluate markers of end-organ malperfusion, including lactic acid >2 mmol/L, ALT >200 U/L or >3× upper limit of normal, creatinine ≥2× upper limit of normal, pH <7.2, metabolic acidosis without another known cause
ECG/Echocardiogram	Evaluate acute ischemia, including ECG and sonographic evidence of STEMI (regional wall motion abnormalities); evidence of LV or RV dilation and systolic dysfunction; valvular pathology
Congestion	Presence or absence of congestion based on physical signs and hemodynamics; elucidation of ventricular involvement (LV vs RV vs BiV)
Triage	Appropriate triage/shock team activation or possible transfer to a higher level of care

Cardiogenic Shock Diagnosis

Diagnostic criteria varies in the literature but generally includes:

- Sustained hypotension: SBP <90 mmHg or a >30 mmHg drop from baseline for > 30 minutes
- Evidence of hypoperfusion (clinical and/or objective evidence)
- Hemodynamic criteria: Cardiac Index <2.2 L/min/m2 with PCWP >15 mmHg

TABLE 1 Common Etiologies of Cardiogenic Shock

Left ventricular failure

- Acute myocardial infarction
- Hypertrophic obstructive cardiomyopathy
- Myocarditis
- Myocardial contusion
- Peripartum cardiomyopathy
- Post-cardiotomy
- Progressive cardiomyopathy
- Septic cardiomyopathy
- Stress cardiomyopathy (takotsubo)
- Ventricular outflow obstruction

Right ventricular failure

- Acute myocardial infarction
- Myocarditis
- Post-cardiotomy
- Progressive cardiomyopathy
- Pulmonary embolism
- Septic cardiomyopathy
- Worsening pulmonary hypertension

Arrhythmia

- Atrial fibrillation or flutter
- Ventricular tachycardia or fibrillation
- Bradycardia or heart block

Pericardial disease

- Tamponade
- Progressive pericardial constriction

Chemotherapeutic, toxic, metabolic

- Calcium-channel antagonists
- Adrenergic receptor antagonists
- Thyroid disorders

Valvular or mechanical dysfunction

- Aortic regurgitation—acute bacterial endocarditis
- Mechanical valve dysfunction or thrombosis
- Mitral regurgitation—myocardial ischemia or infarction
- Progressive mitral stenosis
- Progressive aortic stenosis
- Ventricular septal defect or free wall rupture

Cardiogenic Shock Causes

- Cardiogenic shock complicates about 10% of acute MI
- At UK we see all of these causes of cardiogenic shock, but most common are shock due to acute MI or decompensated HF

Cardiogenic Shock Stages (know this)



Cardiogenic Shock: Principles of Management

- ✓Correct Underlying Cause
- ✓Restore Perfusion to End Organs
- ✓Optimize Hemodynamics
- ✓Supportive Care and Minimizing Complications

(Yes these overlap with each other)

CGS: Monitoring in the CICU



It starts with monitoring:

- Vitals
- Hemodynamics
- Signs of myocardial recovery (or decline)
- Markers of End Organ perfusion/function
- MCS function / complications (if applicable)

CGS: Minimizing complications



CGS: Correct the Underlying Cause

- If the underlying cause can be corrected you can “break the cycle” and improve cardiac output.
- Time is of the essence to avoid progressive systemic hypoperfusion, end organ damage, and myocardial damage
- Examples:
  - PCI for STEMI (most tangible example)
  - Cardioversion for VT
  - Pericardiocentesis for tamponade
  - Lytics for PE
  - Diuresis for decompensated heart failure

    (among numerous other interventions)



CGS: Restore Perfusion

- Best way to do this is to fix the underlying cause
- But what if perfusion is still not adequate, or the underlying cause can’t be readily corrected?
- You need to augment cardiac output, or replace cardiac output (mechanical circulatory support)
- Augment cardiac output by:
  - Optimizing hemodynamics (preload, afterload)
  - Directly enhancing contractility (inotropes)

CGS: Optimizing Hemodynamics

- Aside from directly enhancing contractility with inotropes or replacing cardiac output with MCS, how can we help the heart pump more blood?
- Preload and Afterload!
- Optimizing preload and afterload will increase stroke volume

Optimizing Hemodynamics: Preload

- Preload – the volume of blood in the ventricle at end-diastole (full tank just prior to contraction)
- In cardiogenic shock, preload is generally too high
- More blood does NOT mean more cardiac output, especially in a sick heart.

Too much Preload:







Optimizing Hemodynamics: Preload

- Preload is the of degree of myocardial filament stretch just prior to contraction. The degree of stretching (preload) is a determinate of stroke volume.
- This relationship is depicted by the Frank-Starling Law (see figure)
- In clinical practice, we use LV end-diastolic volume as a measure of preload
- But volumes are tough to measure, so we often use LV end diastolic pressure as a surrogate for preload



Optimizing Hemodynamics: Preload

- The more preload, the more forceful the LV contraction, and thus the more stroke volume
- With too much preload (myocardial stretching), the stroke volume begins to decrease and you "fall off the curve"
- Patient with decompensated heart failure have excess preload and reducing preload (decreasing LVEDP) will increase stroke volume



Optimizing Hemodynamics: Preload

- The stroke volume-preload relationship (ie shape of the curve) is defined by contractility of the heart
- We can “shift the curve” by altering contractility, giving us more (or less) stroke volume per cc of preload
  - Shift the curve up (increase contractility): inotropes, decreasing afterload
  - Shift the curve down (decrease contractility): beta blockers, calcium channel blockers, increase afterload



Optimizing Hemodynamics: Afterload

- Afterload is the load or resistance the heart must overcome as it ejects blood in systole
- The most common way to clinically measure LV afterload is with Systemic Vascular Resistance (SVR)
- Blood pressure ≠ SVR

Optimizing Hemodynamics: Afterload

- SVR is related to cardiac output and pressure change across the circuit
- This relationship is derived from Ohm's law: **V = I x R**
- **ΔP = CO x SVR**
- The ΔP for the LV is equal to the pressure change across the systemic circuit (aorta to right atrium)

$$SVR = \frac{\Delta P}{CO}$$

Where:

- SVR = systemic vascular resistance
- CO = Cardiac Output
- Δ P = pressure change across the circuit

Optimizing Hemodynamics: Afterload

- SVR (afterload) and CO (ie stroke volume) are inversely related
- Afterload and Preload are concordantly related
- If you lower afterload (SVR), the heart can eject more blood (↑CO) during systole and there will be less blood leftover in the ventricle (preload) at the end of systole



Optimizing Hemodynamics: Afterload

- ESPVR (End-Systolic Pressure-Volume Relationship) – max pressure the LV can generate at a given volume.
- Slope of ESPVR across volumes is end-systole elastance (measure of contractility
- **For a given contractility, afterload influences stroke volume (width of the PV loop)**



Optimizing Hemodynamics: Contractility

- Contractility describes the systole function or squeeze of the left ventricle
- Contractility can be best quantified as the stroke volume or cardiac output (when HR is incorporated):

CO = SV x HR



- Remember, we can enhance stroke volume for a given preload by increasing contractility

Optimizing Hemodynamics: Contractility

- How can we measure contractility or stroke volume? Place a Swan or get an Echo!
- Echo:
  - LV volumes
  - LVOT assessment
  - Many surrogates (ejection fraction, strain, etc.)
- Swan:
  - Fick Method
  - Thermodilution

Stroke Volume by Echo







SV = EDV - ESV

HealthCare
GILL HEART INSTITUTE

Summary of Hemodynamics



- Stroke volume is influenced by load (preload and afterload) and contractility
- All 3 parameters should be addressed when treating HF or shock
- There are multiple measures/surrogates of each

CGS: Intropes and Vasopressors

TABLE 2 Vasoactive Agents Used in CS

Category	Agent(s)	Mechanism of Action/Receptor Binding	Dosing	Hemodynamic Effects			
				SVR	BP	CO	HR
Inopressor	Norepinephrine	α1 (+++), β1 (++), β2 (+)	0.05 -1 mcg/kg/min	↑↑	↑↑	↑	↑
	Epinephrine	β1 (+++), α1 (++), β2 (++)	0.01-0.5 mcg/kg/min	↑↑	↑↑	↑↑	↑↑
	Dopamine	D1 (+++), β1 (++), α1 (+)	Low: 2-5 mcg/kg/min Intermediate: 5-10 mcg/kg/min High: 10-20 mcg/kg/min	↑↑	↑↑	↑	↑↑
Inodilator	Dobutamine	β1 (+++), β2 (++)	2-10 mcg/kg/min	↓↔	↓↔	↑↑	↑
	Milrinone	PDE-3 inhibitor	0.125-0.5 mcg/kg/min	↓↓	↓↓	↑↑	↔↑
Vasopressor	Phenylephrine	α1 (+++)	0.1-10 mcg/kg/min	↑	↑↑	↔↓	↔↓
	Vasopressin	Vasopressin receptor	0.01-0.04 U/min	↑↑	↑↑	↔↓	↔↓
Vasodilator	Nitroprusside	NO production	0.3 - 10 μg/kg/min	↓	↓	↑↔	↑↔
	Nitroglycerin	Converts to NO	25-200 μg/min	↓	↓	↑↔	↑↔
Chronotrope	Isoproterenol	β1 (+++), β2 (+++)	2 -20 μg/min	↓	↔	↑	↑↑
	Dopamine	See above					
Inotrope	Levosimendan*	Binds to troponin C, making it more sensitive to calcium thereby improving interaction between troponin C and I	0.05 - 0.2 mcg/kg/min	↓	↓	↑	↔

CGS: Intropes and Vasopressors

TABLE 2 Vasoactive Agents Used in CS

Category	Agent(s)	Mechanism of Action/Receptor Binding	Dosing	Hemodynamic Effects			
				SVR	BP	CO	HR
Inopressor	Norepinephrine	α1 (+++), β1 (++), β2 (+)	0.05 -1 mcg/kg/min	↑↑	↑↑	↑	↑
	Epinephrine	β1 (+++), α1 (++), β2 (++)	0.01-0.5 mcg/kg/min	↑↑	↑↑	↑↑	↑↑
	Dopamine	D1 (+++), β1 (++), α1 (+)	Low: 2-5 mcg/kg/min Intermediate: 5-10 mcg/kg/min High: 10-20 mcg/kg/min	↑↑	↑↑	↑	↑↑
Inodilator	Dobutamine	β1 (+++), β2 (++)	2-10 mcg/kg/min	↓↔	↓↔	↑↑	↑
	Milrinone	PDE-3 inhibitor	0.125-0.5 mcg/kg/min	↓↓	↓↓	↑↑	↔↑
Vasopressor	Phenylephrine	α1 (+++)	0.1-10 mcg/kg/min	↑	↑↑	↔↓	↔↓
	Vasopressin	Vasopressin receptor	0.01-0.04 U/min	↑↑	↑↑	↔↓	↔↓
Vasodilator	Nitroprusside	NO production	0.3 - 10 µg/kg/min	↓	↓	↑↔	↑↔
	Nitroglycerin	Converts to NO	25-200 µg/min	↓	↓	↑↔	↑↔
Chronotrope	Isoproterenol	β1 (+++), β2 (+++)	2 -20 µg/min	↓	↔	↑	↑↑
	Dopamine	See above					
Inotrope	Levosimendan*	Binds to troponin C, making it more sensitive to calcium thereby improving interaction between troponin C and I	0.05 - 0.2 mcg/kg/min	↓	↓	↑	↔

- This chart is key – know and understand it
- There are nuances to the choice of vasoactive agent for individual patients and clinical scenarios, but remember the overall goals are to restore perfusion and maintain organ perfusion

Inotropes and Vasopressors

- **Inotropes** enhance cardiac function by increasing contractility of the myocardium independent of load (ie preload and afterload)
  - Inotropes are usually initiated at a fixed dose which is then adjusted based on perfusion
- **Chronotropes** increase CO by increasing HR (remember: CO = SV x HR)
- **Vasopressors** increase BP by increasing SVR
  - Vasopressors are usually titrated by a MAP goal
- Key Points:
  - Most require a central line and arterial line
  - Most are arrhythmogenic – need to keep an eye on tele
  - Most increase myocardial oxygen demand (can worsen ischemia)
  - Vasoactives are usually attempted before jumping to MCS

Norepinephrine

- Mechanism: Adrenergic agonist.
- Major effect: Inopressor (increases BP, small increase in contractility)
  - Strong Alpha-1 agonist effect even at low doses (vasoconstriction)
  - Beta-1 activity can be seen in higher doses but weaker effect than epinephrine.
- Notes:
  - Coronary flow may increase due to increased diastolic blood pressure and indirect stimulation of cardiac myocytes which release local mediators
  - Will increase SVR which may decrease CO
- Side Effects: increase afterload, arrhythmogenic, peripheral tissue ischemia, possible direct toxic effect on myocytes by protein kinase A activation and calcium influx.

Agent(s)	Mechanism of Action/Receptor Binding	Dosing	SVR	BP	CO	HR
Norepinephrine	α1 (+++), β1 (++), β2 (+)	0.05 -1 mcg/kg/min	↑↑	↑↑	↑	↑

Epinephrine

- Mechanism: Catecholaminergic adrenergic agonist.
- Major Effect: Inopressor (increase BP, HR, and CO)
  - Strong beta-1 agonist leading to increased inotropy and increased chronotropy
  - Strong alpha-1 agonist at higher doses which leads to increase in SVR. At low doses beta-2 activity may predominate leading to peripheral vasodilation (small effect)
- Notes:
  - Enhanced coronary blood flow due to increased DBP and increased relative duration of diastole through local vasodilators
- Side Effects: increase afterload (esp at high doses), arrhythmogenic, peripheral tissue ischemia, possible direct toxic effect on myocytes by protein kinase A activation and calcium influx.

Agent(s)	Mechanism of Action/Receptor Binding	Dosing	SVR	BP	CO	HR
Epinephrine	β1 (+++), α1 (++), β2 (++)	0.01-0.5 mcg/kg/min	↑↑	↑↑	↑↑	↑↑

Dopamine

- Mechanism: adrenergic agonist
- Major Effect: Inopressor (increase BP, CO, and HR)
  - Strong alpha-1 agonist leading to increase in SVR
- Notes:
  - Rarely used at UK with some studies showing increased mortality compared to norepi
  - Can be considered in patients with significant bradycardia
- Side Effects: Increase afterload, reflex bradycardia, increases myocardial oxygen demand

Agent(s)	Mechanism of Action/Receptor Binding	Dosing	SVR	BP	CO	HR
Dopamine	D1 (+++), β1 (++), α1 (+)	Low: 2-5 mcg/kg/min Intermediate: 5-10 mcg/kg/min High: 10-20 mcg/kg/min	↑↑	↑↑	↑	↑↑

Dobutamine

- Mechanism: Synthetic catecholamine, adrenergic agonist.
- Major Effect: Inodilator (decrease SVR and increase contracility)
  - Strong beta-1 and beta-2 agonist effect leading to increased inotropy and peripheral vasodilation (Beta-2 effect)
- Notes:
  - Variable BP response. If CO increases with fall in SVR, BP may go up. If CO does not improve much despite fall in SVR, BP may go down
  - Ordered at a fixed dose, they adjusted based on response (perfusion, side effects, etc.)
- Side Effects: increase afterload (esp at high doses), arrhythmogenic. tachycardia

Agent(s)	Mechanism of Action/Receptor Binding	Dosing	SVR	BP	CO	HR
Dobutamine	β1 (+++), β2 (++)	2-10 mcg/kg/min	↓ ↔	↓ ↔	↑ ↑	↑

Milrinone

- Mechanism: Phosphodiesterase inhibitor, which increases intracellular calcium leading increased contractile and relaxation forces
- Major Effect: Inodilator (decrease SVR and increase contracility)
  - Vasodilation of systemic arterioles decreasing SVR
- Notes:
  - Variable BP response. If CO increases with fall in SVR, BP may go up. If CO does not improve much despite fall in SVR, BP may go down
  - Renally cleared – use with caution in renal failure ("stacking" effect with drug accumulation)
  - Slower onset of action (don't use acutely in a crashing patient) and long half life (2-4 hours)
  - Agent of choice as a "home inotrope" for advanced HF patients
  - Ordered at a fixed dose, they adjusted based on response (perfusion, side effects, etc.)
- Side Effects: arrhythmogenic, increases myocardial oxygen demand

Agent(s)	Mechanism of Action/Receptor Binding	Dosing	SVR	BP	CO	HR
Milrinone	PDE-3 inhibitor	0.125-0.5 mcg/kg/min	↓↓	↓↓	↑↑	↔↑

Phenylephrine

- Mechanism: adrenergic agonist
- Major Effect: Vasopressor (increase BP)
  - Strong alpha-1 agonist leading to increase in SVR
- Notes:
  - Poor choice in most cases cardiogenic shock
  - Occasionally used to increase BP in setting of severe aortic stenosis (fixed outflow obstruction) or highly arrhythmogenic cases (no beta activity so less arrhythmogenic potential)
- Side Effects: Increase afterload, reflex bradycardia, increases myocardial oxygen demand

Agent(s)	Mechanism of Action/Receptor Binding	Dosing	SVR	BP	CO	HR
Phenylephrine	α1 (+++)	0.1-10 mcg/kg/min	↑	↑↑	↔↓	↔↓

Vasopressin

- Mechanism: Vasopressin receptor agonist
  - V1 receptor agonist: vasocontriction (binding receptors on vascular smooth muscle causing vasoconstriction)
  - V2 receptor agonist: antidiuretic (increased water reabsorption via increased permeability in the renal collecting tubules)
- Major Effect: Vasopressor (increased BP)
- Notes:
  - Will increase SVR which may decrease CO
  - Used as an "add on" to another vasopressor (norepinephrine) at a fixed dose, usually in distributive shock
- Side Effects: increases afterload, vasoconstriction of small coronary arteries, hyponatremia

Agent(s)	Mechanism of Action/Receptor Binding	Dosing	SVR	BP	CO	HR
Vasopressin	Vasopressin receptor	0.01-0.04 U/min	↑↑	↑↑	↔↓	↔↓

Nitroprusside

- Mechanism: cyclic GMP mediated NO production to relax vascular smooth muscle cells
  - Acts directly on venous and arteriolar smooth muscle
- Major Effect: Vasodilator (potentently reduces SVR)
- Notes:
  - Can be very effective in cardiogenic shock when SVR is very high and there is sufficient myocardial contractile reserve to augment CO
  - Metabolized to cyanide – minimize risk of cyanide toxicity by limiting Nitroprusside use to <2 days, dose <2 mcg/kg/min, and avoidance in renal dysfunction (~Cr <2)
- Side Effects: cyanide toxicity, methemoglobinemia, hypotension

Agent(s)	Mechanism of Action/Receptor Binding	Dosing	SVR	BP	CO	HR
Nitroprusside	NO production	0.3 – 10 µg/kg/min	↓	↓	↑↔	↑↔

Nitroglycerine

- Mechanism: converts to NO, which stimulates vascular smooth muscle cell relaxation
- Major Effect: Vasodilator (modestly reduces SVR)
  - Venodilation > arteriolar dilation
  - Venodilation reduces myocardial preload → reduces myocardial O2 demand
  - Anti-anginal: Dilates coronary vasculature and improves collateral flow to ischemic regions
- Notes:
  - Avoid in patients taking phosphodiesterase inhibitors (delay use >24hrs after sildenafil, vardenail; and >48hrs after tadalafil)
- Side Effects: headache, tachycardia, hypotension

Agent(s)	Mechanism of Action/Receptor Binding	Dosing	SVR	BP	CO	HR
Nitroglycerin	Converts to NO	25-200 µg/min	↓	↓	↑↔	↑↔

Isoproterenol

- Mechanism: adrenergic agonist
- Major Effect: Chronotrope (increase HR, small increase in CO)
  - Strong B1 and B2 activity
- Notes:
  - Major use is to drive up HR
  - Used in symptomatic bradycardia or overdrive ‘pacing’ in Torsades de Pointes
- Side Effects: Arrhythogenic, increases myocardial oxygen demand

Agent(s)	Mechanism of Action/Receptor Binding	Dosing	SVR	BP	CO	HR
Chronotrope	Isoproterenol	β1 (+++), β2 (+++)	2 -20 µg/min	↓	↔	↑	↑↑

Mechanical Circulatory Support

MCS Overview

- MCS is used to augment cardiac output to increase end organ perfusion when the heart can't adequately do the job itself
- It is taking over part of the workload of the heart (sort of like dialysis for kidneys)
- MCS is not treating an underlying – just keeping the organs intact until the heart can (hopefully) recovery

MCS Indications

- Cardiogenic shock (MCS doesn't work for other causes of shock where cardiac output is not the problem)
- Failed / failing non-MCS treatments (SCAI stage class D or E) such as inotropes
- Other organs are not too far gone
- Meaningful chance of recovery
  - Or a bridge to durable support (LVAD or heart transplant)



ECMO (and all MCS) is a Bridge to…



- Know the end-game at the beginning
- Is this MCS a bridge to recovery or durable support?
- For durable support, need to know if patient a candidate for an LVAD or heart transplant
- Bridge to decision is not advisable


Recoverable?
Degree of end-organ damage
Ideal Patient
Frailty, chronic comorbidities, social support?
Patient Substrate
Cause of cardiogenic shock
Reversible?

Contraindications/factors to consider

- Age (no strict cut off)
- Severe chronic end-organ failure (cirrhosis, ESRD)
- Aortic dissection
- Malignancy
- Coagulopathy
- Peripheral vascular disease (for peripheral VA ECMO)
- Not a candidate for durable support and chronic cardiomyopathy

Patient Selection is key

- Unfortunately, mortality in cardiogenic shock is very high even with the best possible care
- The goal is to identify patients (early) who have a chance of recovery
  - Initiating MCS before cardiac arrest has been consistently shown to have better outcomes
- Only 1 randomized trail has shown a mortality benefit with MCS in cardiogenic shock
  - DanGer Trial NEJM 2024 randomized patients to microaxial flow pump (Impella) vs standard of care

Survival by Indication with and without cardiac arrest



	Pulmonary Embolism N=49	Acute Myocardial Infarction N=51	Acute Heart Failure N=30	Ventricular Arrhythmia N=10	Chronic Heart Failure N=27	All Indications N=167	eCPR N=47
Indication With Cardiac Arrest N=57	6.3	26.1	11.1	66.7	33.3	22.8	17.0
Indication Without Cardiac Arrest N=110	72.7	42.9	66.7	50.0	37.5	55.5	
Indication N=167	51.0	35.3	50.0	60.0	37.0	44.3	

Survival is much higher if MCS is initiated prior to cardiac arrest regardless of the underlying shock etiology

Whiteside et al. J Int Care Med. 2023; 38(2):202-7.



Non-surgical Patient in Cardiogenic Shock Considered for VA-ECLS

Precannulation Variables Predicting Inpatient Mortality After Initiation of VA-ECLS

LACTATE Score

Lactate*

Anemia*

Coma: Glasgow Coma Scale < 8

resusci**TATE**d cardiac arrest

**Entered as continuous variables*

Derivation (n=135) AUC = 0.760
SOFA Score AUC = 0.699
SAVE Score AUC = 0.568
Validation (n=30) AUC = 0.710

LACT-8 Score

Lactate > 8 mmol/L

Anemia: hemoglobin < 8 g/dL

Coma: Glasgow Coma Scale < 8

resusci**TATE**d cardiac arrest

(1) point each, max. 4

Derivation (n=135) AUC = 0.742
Validation (n=30) AUC = 0.730

LACT-8 Score ≥ 3

97.9% Specificity
95.5% Positive Predictive Value

Hillerson et al. Catheterization and cardiovascular interventions. 2022. DOI: 10.1002/ccd.30106.

A tool for patient selection from UK

HealthCare® GILL HEART INSTITUTE

Types of MCS – lots of factors to consider

- Type of support: LV, RV, or biventricular support
- Amount of cardiac output provided
- Access and placement
- Hemodynamic impact
- Duration of support (hours, days, weeks)
- Contraindications

MCS General Considerations

- Patient selection is critical – identify patients that are failing non-MCS therapies, but have a chance to survive with a little more help
  - The earlier that MCS is initiated, the better the change at a good outcome
- Know the end game at the beginning – what's the plan to get the patient off MCS? Candidate for advanced HF therapies?
- MCS is dangerous – assess for complications vigilantly (they are common)

- Consider MCS removal daily – barriers to removal?
  - MCS should be removed when risks/complications are greater than benefits of ongoing support
  - Sometimes patient isn't all the way recovered when MCS is removed

MCS Complications

- Vascular injury
- Bleeding
- Stroke
- Hemolysis
- Ischemic limb
- Infection
- Pulmonary edema (VA-ECMO)
- North-South Syndrome (VA-ECMO)

How to decide what MCS is needed?

- First determine if LV, RV, or biventricular support is needed
  - Cause of shock (ie. Acute LAD MI probably only needs LV support)
  - Review Swan numbers (if available)
  - Imaging (how are LV and RV function on imaging)
- How much support (cardiac output replacement) is needed?
- Assess patient for specific contraindications for MCS devices
- Predicted duration of support

FIGURE 6 Common tMCS Devices Used in CS



	Impella RP Flex	RA-PA pVAD	VA-ECMO	IABP	Impella CP	Impella 5.5
Max flow	3.0 - 4.0 L/min	4.0 - 5.0 L/min	5.0 - 7.0 L/min	0.5 - 1.0 L/min	3.0 - 4.3 L/min	5.0 - 6.0 L/min
Max pump speed	33,000 rpm	7,500 rpm	6,000 rpm	NA	46,000 rpm	33,000 rpm
Mechanism	Axial flow continuous pump (RA-to-PA)	Centrifugal flow continuous pump (RA-to-PA)	Centrifugal flow continuous pump (RA-to-AO)	Balloon inflation-deflation (AO)	Axial flow continuous pump (LV-to-AO)	Axial flow continuous pump (LV-to-AO)
Sheath size	23 F venous peel-away	29 or 31 F venous (inflow)	15-24 F arterial 19-25 F venous	7-8 F arterial	14 F arterial peel-away	23 F arterial peel-away
Typical insertion/ placement	Internal jugular vein	Internal jugular vein	Femoral vein (drain) Femoral artery (return)	Femoral artery or Axillary artery	Femoral artery or Axillary artery	Axillary artery
Direct LV unloading	-	-	-	-	+++	+++
Direct RV unloading	+	+	+	-	-	-
Afterload	-	-	↑↑↑	↓↓	↓	↓
Coronary perfusion	-	-	↑↑	↑↑	↑↑	↑↑

Which ventricles need support?

- A failing ventricle is determined by degree of output and backed up blood/pressure.
  - LV: LV stroke volume and LA pressure (PCWP)
  - RV: RV stroke volume and RA pressure (CVP)
- Cardiac Power Output (CPO) is a key hemodynamic value to identify need for MCS.
  - CPO reflects the heart's ability to generate pressor (MAP) and flow (CO) – essentially tissue perfusion
  - CPO <0.6 + PCWP >15 indicates LV support needed
  - CPI (Cardiac Power Index) is CPO normalized to BSA (sub out CO for CI in the calculation)
- Pulmonary Artery Pulsatility Index (PAPI) reflects RV ability to generate pressure and the degree of back up (RA pressure)
  - PAPI < 1 indicates need for RV support

Hemodynamic Calculations

(1) Cardiac Power Output (CPO) $\frac{MAP \times CO}{451}$

(2) Pulmonary Artery Pulsatility Index (PAPI) $\frac{sPAP - dPAP}{RA}$



There are many shock algorithms in the literature. Most incorporate CPO and PAPI.

LV Support Devices

- IABP
- Microaxial Flow Pump (Impella)



Mechanical Circulatory Support

Intraaortic Balloon Pump (IABP)



- Type of support: LV
- Amount of support: 0.5 to 1LPM (minimal)
- Access: femoral artery (rarely axillary)
- Duration of support: hours to days
- Key Contraindications: >mild aortic regurgitation, aortic dissection, severe PAD, coagulopathy precluding anticoagulation, irregular or very fast rhythm (relative)

IABP



- **Counterpulsation**: inflates during diastole and deflates during systole
- Systole – balloon deflates as AV opens and heart ejects blood. Deflation sucks blood out to agument CO and lower SBP
- Diastole – balloon inflates when AV is closed to push blood back into the coronary arteries and great vessels of the aorta. DBP increases
- Overall increase in MAP

Excellent resource for more on IABP: https://derangedphysiology.com/main/required-reading/cardiovascular-intensive-care/Chapter-405/benefits-diastolic-augmentation-iabp

IABP Triggering



1:1 assist (every beat)

- IABP can be programmed to trigger inflation based off of the ECG or by aortic pressure
  - ECG: balloon inflates at middle of T wave and deflates at R wave
  - Pressure: senses dicrotic notch (AV closing) on arterial waveform, which initiates inflation
- Can set balloon to assist every beat, every other beat, or every third beat (1:1, 1:2, 1:3)

IABP – Positioning





- Balloon should be positioned in the descending thoracic aorta distal to the left subclavian artery and proximal to the renal arteries
- On CXR, tip of balloon should be <2cm above the left main stem bronchus
  - Too proximal – LUE ischemia
  - Too distal – renal failure
- Consider daily CXR to monitor position

IABP Indications

IABP-SHOCK II Trial. NEJM. 2012



No mortality benefit in pivotal randomized trial

- Indicated in acute MI-associated shock (esp. with LM disease or mech. complications) or advanced HF-associated shock
- Rarely used at UK given minimal cardiac output, complication risks, available of other MCS devices, and lack of evidence of efficacy
  - We get a lot of transfers with IABP in place from OSH

3: No benefit	B-R

3. In patients with AMI and cardiogenic shock, the routine use of intra-aortic balloon pump (IABP) or venoarterial extracorporeal membrane oxygenation (VA-ECMO) is not recommended due to a lack of survival benefit.[5-9]

IABP weaning

- To test if patient can maintain perfusion without the pump, turn assist down to 1:3 (essentially no support at this)
  - Note: patient needs anticoagulation if pump is not at 1:1
- If patient remains HD stable and chest pain free, can likely be removed
- Removed at bedside in the ICU by fellow or attending
  - Wait to remove until ACT <150
  - Requires at least 15 minutes of manual pressure
  - Pulse ox on ipsilateral big toe (monitor manual pressure)
  - Have back up available
  - Consider FemStop for larger patients

(not like this)

Microaxial Flow Pump (Impella)



- Type of support: LV
- It comes in 2 types of sizes (CP and 5.5)
- Amount of support:
  - Impella CP: 3 – 4 LPM
  - Impella 5.5: 5 – 6 LPM
- Access:
  - Impella CP: femoral artery
  - Impella 5.5: axillary artery (surgical cut down)
- Duration of support:
  - Impella CP: days
  - Impella 5.5: days to weeks
- Key Contraindications: LV thrombus, mechanical AV, severe AS, aortic dissection, severe PAD, coagulopathy precluding anticoagulant or insertion

Impella





- Built on the principle of the Archimedes Screw
- Sucks blood out of the LV and dumps it into the aorta
- The amount flow is determined by the size of the threads and speed it spins (RPM)

Impella Indications



DanGer Shock Trial. NEJM. 2024

- Impella CP: cardiogenic shock or to assist a high risk PCI in the cath lab
- The only MCS device with a positive randomized trial (barely) showing a mortality benefit in cardiogenic shock
- Impella 5.5: long-term support, often in patients waiting for a heart transplant.
  - Axillary access, allowing for ambulation
- Does not provide RV support, so not a good MCS choice for biventricular failure

Impella Console

Aorta and LV pressure waveforms

Motor Current

Flow provided (determined by RPM and P level)



Performance level
- Set P1 to P9
- The higher the P, the faster the RPM, and more support provided

Impella Alarms

Impella has fallen out into aorta (no motor current and LV waveform looks like aortic waveform

- The console will alarm if it detects something abnormal (drop in flow, abnormal pressure in the LV or aorta, etc.)
- The SmartAssist feature will try to tell you what the problem is
- For almost any troubleshooting, next step includes bedside echo re Impella position

Impella Positioning

- Position is assessed by echo by measuring the distance from AV to the inlet cage from PLAX view
- Proper position:
  - Impella CP: 3.5cm from AV
  - Impella 5.5: 5.5 cm from AV
- Malposition is very common
- Too deep: inlet sucks onto LV walls causing drop in flow
- Too shallow: risk device falls out into aorta

Impella Complications

- Complications are very common with this device
  - Number needed to harm was 6(!) in the DanGer Trial
- Vascular access site damage and bleeding (quite common)
- Limb Ischemia
- Hemolysis – worse at higher RPM
- Stroke
- Malposition
- Aortic regurgitation
- Infection

Right Ventricular Failure and MCS

- RV failure
- RV support devices:
  - Impella RP
  - Protek Duo with Tandem Heart
  - Tandem RVAD



The Right Ventricle

- Compared to the LV, the RV is a thin walled (2-3 mm thick) chamber designed to pump against the lower pressures and highly compliant pulmonary circuit
- The RV only requires 1/6th energy expenditure to maintain the same stroke volume as the LV (PVR is 1/10th of the SVR in normal patients)
- The RV is more resilient to ischemia due to thin walls

Left Ventricle

Right Ventricle

RV Failure



- Compared to the LV, the RV is much more sensitive to afterload (elevated PASP and PVR)
- RV stroke volume declines precipitately to an acute rise in afterload.
- A drop in SV will leave more blood “left over” in the RV after each beat, causing RV volumes to increase, leading to chamber dilation (acute response)
- RV hypertrophy can occur with chronically high afterload.

The nuisance neighbor

- The LV and RV share a wall, the interventricular septum (IVS), and the function of one ventricle effects the other (**ventricular interdependence**)
- The position of IVS is determined by the relative pressures of the LV and RV
- In RV failure, the IVS is pushed leftward (D-sign on echo)
- Thus, LV geometry is altered even though it may not be the ventricle affected by the disease state
- The abnormal LV shape leads to impaired LV filling and reduced SV volume.



Right Failure

- Main causes:
  - Contractile failure: RV infarct (acute MI)
  - Pressure overload: PE or Pulmonary hypertension
  - Volume overload: Right sided valve disease, back up from left heart disease
- Main Treatments:
  - Optimize preload (may need volume or diuretics)
  - Reduce afterload – pulmonary vasodilators (inhaled epoprostenol, nitric oxide)
  - Improve contractility – inotropes (typically dobutamine, milrinone)
  - Buy time for the RV to recover – RV MCS

Impella RP



- Amount of support: 3 – 4 LPM
- Access: Right IJ or femoral vein
- Duration of support: hours to days
- Propels blood from RA to the PA, bypassing the RV
- Mechanism: axial flow pump (same as LV impella)

Protek Duo Cannula



a. Protek Duo Cannula
b. Protek with Tandem Heart
c. Protek with Tandem Heart and oxygenator

- Mechanism: a dual lumen cannula (one for blood drainage and the other for return) that is connected to a ex situ pump (usually the Tandem heart centrifugal pump)
- Access: Right IJ
- Amount of support: 4 – 5 LPM
- Duration of support: days to weeks
- Can be combined with Impella 5.5 (axillary) for long-term biventricular support
- Oxygenator can be spliced into circuit (“Oxy RVAD”)

Tandem Heart RVAD



- Direct surgical cannulation of RA and pulmonary artery
- Mechanism: ex situ centrirugal pump that drains blood from the RA and returns to the PA, bypassing the RV
- Amount of support: 3 – 4 LPM

Venoarterial-Extracorporeal Membrance Oxygenation (VA-ECMO)

- Type of support: Biventricular (+ oxygenation)
- Amount of support: up to 7LPM of cardiac output (full support)
- Access: variable configurations
- Duration of support: days
- Key Contraindications: >mild aortic regurgitation, aortic dissection, severe PAD (precluding access), coagulopathy precluding anticoagulation, comorbid life limiting illness (cirrhosis, malignancy, severe pulmonary disease, etc.)

Excellent ECMO learning resource: https://www.learnecmo.com/home

VA-ECMO Configurations

- Peripheral VA ECMO: femoral artery and vein cannulation
- Central VA ECMO: direct (surgical) cannulation of aorta and pulmonary artery
- Remix:
  - LAVA-ECMO (more on this later)
  - ECMO + 2nd support device (IABP, Impella)





VA-ECMO Components



<u>Oxygenator</u>
Countercurrent circulation with sweep gas flowing opposite direction of blood

<u>Centrifugal Pump</u>
Creates negative pressure (suction)



Drainage (venous) cannula in femoral vein
Return (arterial) cannula in femoral artery

VA-ECMO Complications

- Up to 50% complication rate
- Variable oxygenation (North-South Syndrome)
- Afterload (LV distention, pulmonary edema, etc.)
- Limb Ischemia
- Coagulopathy





VA-ECMO Physiology

2 separate circuits:

- Native circuit: RA→RV→PA→lungs→LA→LV→Ao
- ECMO circuit: RA (IVC)→ECMO→Ao

- Both must be managed
  - Monitor native circuit with right radial A-line



VA-ECMO Physiology

- The native circuit and EMCO circuit both expel blood into the thoracic aorta – antegrade from native circulation and retrograde from ECMO
- The blood will meet somewhere in the aorta – mixing cloud of blood from the native circuit and blood from the ECMO circuit
- The ECMO blood will be fully oxygenated from the oxygenator
- The native blood oxygenation is dependent upon lung function



VA-ECMO Physiology

- If the native circulation is perfusing with poorly oxygenated blood, ischemia can develop in the effected area
- The first tissues to be effected will the right upper extremity
- For this reason, we always place a right radial arterial line for oxygenation monitoring (serial ABG's)



North-South Syndrome (Harlequin Syndrome)

- If the mixing cloud shifts beyond the take off of the left common carotid, anoxic brain injury can occur
- North South Syndrome occurs when the mixing cloud has shifted beyond the left subclavian artery, so the upper extremities, head, and neck are perfused by poorly oxygenated blood from the native circulation
- **Beware of North-South Syndrome in a patient on VA ECMO with bad lungs (poor native oxygenation) and a recovering heart (mixing cloud shifting more and more distal in the aorta)**



VA-ECMO Physiology – Afterload

- With VA-ECMO ↑↑↑ afterload – due to return cannula pumping 4 LPM of blood retrograde into the aorta
- The solution to excess afterload is **LV venting**



↑ Afterload
↑ LVEDP
↑ LV wall stress
↑ LV distention
↑ LA pressure (PCWP)
Pulmonary Edema (ECMO lung)
↓ Coronary Perfusion Pressure
Ischemia Arrhythmias
↓ Contractility
↓ AV Opening
AV Thrombosis

VA-ECMO LV Venting

- There are multiple LV venting strategies – the goal is too offload the LV to lower LVEDP
- Note: When using a second support device (IABP, Impella) for LV venting, the second support device is not there to increase CO – only to reduce LVEDP. ECMO supplies all CO.

ECMO + IABP



ECMO + Impella



LAVA-ECMO



Others: Interatrial septostomy, surgical LV apical drain

LAVA (Left Atrium Veno-Arterial)-ECMO



- Instead of leaving the drainage cannula in the IVC/RA, it is advanced across the interatrial septum
- This requires a interatrial transseptal puncture under TEE guidance
- The drainage cannula has multiple side ports along the distal end which are used to suck blood into the ECMO circuit from both the RA and LA
- Reduces LA volume → reduction in LA pressure, LVEDP, and less pulmonary edema.
- This strategy bypasses the need for a second support device – fewer complications

Vascular Complications

- Large cannulas (14-21 Fr arterial sheaths)
- Risk factors: PAD, small body size, large(r) cannulas
- Limb ischemia is often catastrophic
  - Significant morbidity and mortality
- Solution: distal perfusion catheter.



Coagulation management – bleeding and clotting

- Can get complicated…
- “Locally” (the circuit) is prone to clotting
  - Worse at lower flows
- “Globally” (the patient) prone to bleeding
  - Access sites
  - Hemolysis - Shearing of clotting factors – Worse at higher flows
  - Critical illness and renal failure
- Need anticoagulation – but lower doses than other conditions
  - First line anticoagulation is bivalirudin (aPPT 60-80)

VA-ECMO Weaning



Patient may be ready to wean from ECMO if:

- Underlying cause of shock has been corrected
- End organ perfusion intact or improving
- Little to no pressors/inotropes
- Tolerates wean trial: turn down flow to 1.5 LPM

Non pulsatile arterial line waveform

Pulsatility improved



VA-ECMO Failure to Wean

- Need to keep family updated and informed.
- Does the heart need more time to recover?
- Is the patient a candidate for LVAD or heart transplant?
- Palliative care / hospice
- Bridge to axillary artery Impella 5.5
  - LV support only
  - Surgical cut down in the OR
  - Allows for extubation and ambulation



Veno-Venous-ECMO (VV-ECMO)



- Used for refractory hypoxia <u>without</u> cardiac impairment
- Does not provide any LV and RV hemodynamic support.
- No arterial access – blood is removed and returned into venous circulation
- The rest of the circuit is the same as VA-ECMO
- Rarely used in the CCU

Veno-Venous-ECMO (VV-ECMO)



- Avalon Cannula is a dual lumen cannula allowing for a single venous access site
- One lumen for blood drainage and one lumen for blood return

Excellent ECMO learning resource: https://www.learnecmo.com/home

MCS Codes

- Regardless of support device or underlying rhythm, the first step is to determine if MCS is providing flow or not.
- If no flow, **start CPR**
- Device Specifics no flow needing CPR:
  - IABP – CPR and set pump trigger to **pressure** (not EKG)
  - Impella – CPR and set to P2
  - VA-ECMO – CPR and check the circuit for mechanical issues (cannula dislodged, clotting in the circuit)
  - Durable LVAD – CPR while avoid direct pressure over the LVAD

LVADs 101

Left Ventricular Assist Device (LVAD)

- An LVAD is a portable, battery-operated pump that is implanted inside the body.
- It is powered by a centrifugal pump that sucks blood form the LV and dumps it into the ascending aorta
- A driveline exists the body from the upper abdomen and connects to rechargeable batteries.



Left Ventricular Assist Device (LVAD)

- Implanted in patients:
  - Who are unable to receive a heart transplant (destination therapy)
  - Who are not eligible for a heart transplant immediately but may be in the future (bridge to transplant)
- The only approved LVAD on the market is the HeartMate III LVAD (HM3).
- Patients require warfarin for anticoagulation with a lower INR goal (1.3 – 1.7)
- The pump provides continuous flow, so patients do not really have a systolic and diastolic blood pressure. Blood pressure is measured by the MAP

LVAD contraindications

- Right heart failure
- Renal Failure
- Refractory ventricular arrhythmias (typically worsen after LVAD placement)
- Uncontrolled infection
- Inability to tolerate anticoagulation
- Lack of psychosocial support

LVAD Complications

- Bleeding – very common
  - Acquired VwF deficiency occurs from continouous flow / pump shear forces.
  - Increased pressures in the GI tract can lead to AVM's / angiodysplasia.
- Hemolysis – higher RPM on the pump speed leads to worse hemolysis
- Pump Thrombosis – usually when INR is subtherapeutic
  - Symptoms: fatigue, dark urine, scleral icterus, left heart failure
  - LVAD Alarms: increasing pump power, changes in pulsatility index,. Power spikes, low flows, and increased PI (as native AV opens more).
  - Best test = LDH >1150 IU/L
- Stroke
- Infection – especially associated with the driveline

LVAD Complications (cont)

- Arrhythmias – ventricular arrhythmias very common from irritation of the inflow cannula which sits inside the LV
- Right Heart Failure – LVAD does not support the right heart
  - Sometimes the degree of RV dysfunction is not recognized prior to implantation

LVAD Interrogation and Troubleshooting

Parameters:

- Speed (rpm's)
- Flow (LPM)
- Power (watts)
- Pulsility Index

LVAD Interrogation and Troubleshooting

Speed

- The only parameter that is set, the rest of calculated from RPM and pressure sensors
- Typical range 2 – 10K RPM

LVAD Interrogation and Troubleshooting

Flow

- Flow through the pump which is estimated using the RPM and pressure gradient between the inflow and outflow
- Typical range 4 – 7 LPM

LVAD Interrogation and Troubleshooting

Power

- Amount of energy required to drive the motor
- The more RPM, the more power required
- Typical range 4 – 6 watts

LVAD Interrogation and Troubleshooting

Pulsility Index (PI)

- Measure of the flow “pulse” coming from the LV into the pump
- As the heart contracts flow increase and decreases like a wave
- Under normal circumstances, it is a measure of heart’s native contractility
- Typical range 1 – 10

Low Flow Alarm

- Low RPM
- Low preload to the pump
  - Hypovolemia
  - RV failure
  - Tamponade
  - Thrombus
  - Malposition / kink
- High afterload
  - Systematic hypertension
  - Outflow obstruction

Pulsatility Index (PI) Alarms

- Increased PI
  - Increase preload
  - Increased native LV contractility
- Decreased PI
  - Worsening native LV contractility
  - Decreased preload
  - Reduced afterload
  - Inflow/outflow cannula obstruction
- PI Event – when PI measurement differs from the average PI by >45%, pump automatically slows and gradually returns to normal speed.

LVAD Troubleshooting Summary

What significant changes am I seeing?			Possible causes to evaluate...
Power (Displayed Flow)	Pulsatility Index (PI)	Pump Speed*	
⇩	⇩	Unchanged (Steady)	• Inflow/outflow obstruction (i.e. cannula placement or kink) • Hypertension • Arrhythmia • Reduced left ventricular function
⇧	⇩ (or constant)	Unchanged (Steady)	• Device thrombus on rotor (Flow estimate may be erroneous due to increased pump power consumption) • Hypotension • Vasodilation • Initial patient response to exercise

⇩	⇧	Fluctuating	• Suction event
			  ○ Pump speed is too high
			  ○ Decreased pre-load such as hypovolemia, tamponade, right heart failure or pulmonary hypertension, bleeding or vasodilation
			  ○ Poor inflow cannula positioning (cannula obstructed by LV wall or septum)
			NOTE: When a suction event is detected, the pump speed is automatically reduced below the fixed speed setting to the low speed limit setting (only when fixed speed setpoint is > low speed limit). Once suction events are no longer detected, the speed gradually increases back to the original fixed speed setting. This drop in speed is also associated with a reduction in pump flow and is reflected in the displayed flow estimate

⇧	⇧	Unchanged (Steady)	• Normal operating conditions with increased physiologic demand • Myocardial recovery and exercise • Fluid retention and exercise

*Constant speed should always be maintained by controller unless there is a suction event.

ACS



Myocardial Infarction Types



The key difference between Type I vs. Type II MI is the presence/absence of plaque rupture (From 4th Universal Definition of MI, 2018, PMID 30165617)

Type I MI

- Defined as an infarction is **due to coronary plaque rupture/erosion**
- Diagnosis: Universal Definition of MI:
  - Biomarker rise/fall *AND* > 1 of:
    - Ischemic symptoms
    - Ischemic ECG changes
    - New Q waves
    - Imaging findings (new WMA or evidence of loss of myocardium)
    - Coronary thrombus on angiography/autopsy



Type II MI

- Defined as infarction unrelated to coronary plaque disruption (due to myocardial oxygen supply-demand imbalance)
- Same Universal Definition of MI as type I event (see previous slide)
- There is often preexisting coronary stenosis (limits supply)
- Examples:
  - Anemia
  - Sepsis
  - Shock
  - Respiratory failure/hypoxia
  - Coronary vasospasm
  - Tachy or bradyarrhythmia
  - Severe hypertension



Definition of STEMI

- Measure the ST segment at the J point.
- Compare ST segment deviation to isoelectric segment (PR or TP segment)
- ST segment elevation >1mm is significant in all leads except V2 and V3
- STEMI is diagnosed if ST segment elevation is present in 2 or more anatomically contingent leads





Anatomic Contiguous Leads



Lateral Leads	I, aVL, V5 - V6	LCx or Diagonal of LAD
Inferior Leads	II, III, aVF	RCA and/or LCx
Anterior/Septal Leads	V1 - V4	LAD

ECG STEMI Equivalents

- Cath lab should be activated for patients with these ECG patterns and a concerning clinical picture
  - Anginal chest pain
  - Elevated/rising troponin
  - Electrical instability
  - Hemodynamic instability



STEMI

- Patients will STEMI go immediately to the cath lab for goal ‘door to balloon time’ of 90 minutes
- After the cath lab these patients are admitted to the CCU for stabilization and monitoring for post MI complications
- 10% of acute MI’s are complicated by cardiogenic shock



STEMI

- You will hear about STEMI admissions from the fellow or attending
- If you have time, go down to the cath lab and watch
  - Learn something
  - Find out everything that happens during the cath (arrhythmias, meds given, etc.)
- Review MAR to make sure critical meds have been given / ordered

STEMI – Medication Checklist

- ✓Aspirin
  - Loading dose 325 mg (prior to cath), then 81 mg daily
- ✓P2Y12 Inhibitor
  - Ticagrelor 180 mg loading dose, then 90 mg BID
  - Clopidogrel 300 or 600 mg loading dose, then 75 mg daily
  - Prasugrel 60 mg loading dose, then 10 mg daily (contraindicated if prior TIA/CVA)
- ✓High Intensity Statin
  - Atorvastatin 40-80 mg daily
  - Rosuvastatin 20-40 mg daily
- ✓Beta Blocker (if no concerns for shock or bradyarrhythmias)
  - Metoprolol (titrate with tartrate, then succinate (XR) prior to discharge)
  - Carvedilol (hypertensive patients)
- ✓ACE-Inhibitor or ARB (if LVEF <40% and no concerns for shock)
  - Captopril (short acting ACEi for borderline hypotensive or unstable patients)
  - Lisinopril, Enalapril, valsartan, losartan, etc.

STEMI – Checklist

<u>On arrival to the CCU:</u>

- Post-PCI EKG
- Post-PCI Echocardiogram

<u>On Discharge:</u>

- Sublingual nitroglycerin on discharge
- Tobacco cessation / nicotine replacement
- Follow up with cardiologist
- Referral to cardiac rehab

Post STEMI Complications

- Recurrent ischemia
- Mechanical Complications (rare in PCI era)
- LV thrombus
- Cardiogenic shock (see dedicated section)
- Arrhythmias

Post STEMI Ischemia

- Causes:
  - Reperfusion injury (occurs after coronary vessel is opening with down stream damage)
  - Acute re-occlusion (stent thrombosis)
  - Unrelated territory ischemia (supply-demand in setting of inflammation, hemodynamic instability, arrhythmias, etc.)
- Workup:
  - EKG – compare ST segments to immediate post cath EKG
  - Echo – assess for new or worsening wall motion abnormalities
- Management:
  - Acute stent thrombosis requires repeat intervention
  - Antianginal medications

Mechanical Complications

- Papillary Muscle Rupture
- Ventricular Septal Defect
- Free wall rupture



Papillary Muscle Rupture

- Predictors:
  - Usually due to MI involving the LCX or RCA
  - Usually the posteromedial papillary muscle which blood supply comes from the PDA
    - The anterolateral papillary muscle has dual blood supply from LAD and LCX
- Presentation:
  - Abrupt dyspnea and hypoxia (flash pulmonary edema)
  - Hypotension
  - MR murmur (can be absent due to “wide open” regurgitation)
- Management:
  - Urgent CT surgery consultation
  - Supportive care for shock
  - Respiratory support (often mechanical ventilation)

Papillary Muscle Rupture



Segment of a papillary muscle oscillating across the mitral valve causing a flail anterior leaflet



Severe mitral regurgitation

Ventricular Septal Defect (VSD)

- Predictors:
  - Older age
  - Female > male
  - No or delayed revascularization
  - Large anterior MI (LAD)
- Presentation:
  - Hypotension
  - Heart failure symptoms
  - Harsh systolic murmur





Ventricular Septal Defect (VSD)



- Management:
  - Supportive care until surgical or interventional fix
  - Prevent further ischemia
  - Consider MCS if shock
- Surgical patch
  - Risk of surgery is very high in immediate post MI period
  - Ischemia myocardium is highly friable and can't hold sutures
- Percutaneous closure device
  - Unable to close if VSD if very large



VSD Occluders

Free Wall Rupture

- Predictors:
  - Older age
  - Female > male
  - No or delayed revascularization
  - Large anterior MI (LAD)
- Presentation:
  - Chest pain
  - Ventricular arrhythmias
  - Hypotension
  - Rapid tamponade (hemopericardium)
  - Sudden cardiac death
- Almost universally fatal



Free Wall Rupture



LV wall rupture with pseudoaneurysm



LV free wall rupture

Hemopericardium

Mechanical Complications Summary

	Ventricular Septal Rupture	Free Wall Rupture	Papillary Muscle Rupture
Time course	Bimodal peak; within 24 h and 3-5 days; range 1-14 days		
Clinical manifestations	CP, CHF, Hypotension	CP (anginal or pericardial), Hypotension, Nausea, Restlessness, Arrthythmias, SCD	Abrupt SOB, Flash Pulmonary Edema
Physical findings	Harsh holosystolic murmur, (+) thrill, (+) S_3, accentuated S_2, pulmonary edema, RV and LV failure, cardiogenic shock	JVD (29% of patients), pulsus paradoxus (47%), PEA, cardiogenic shock	Soft or no murmur, no thrill, severe pul edema, ± RV overload, cardiogenic shock
Echo findings	Septal defect, L>R color flow through septum, RV overload	± >5 mm effusion, ± dense pericardial echoes, ± tear; ± tamponade	Torn muscle or chordae , flail leaflet, severe MR on color flow, hyper LV
Right-heart catheterization	O_2 sat step-up from RA to RV, large V waves in RA	± Classic signs of tamponade	No O_2 Sat step-up Large V waves, Very high PCWP



Pulmonary Embolism

PE Classification

- Pulmonary Embolism is a very common clinical condition with a highly variable prognosis depending on the severity of the PE
- Overall, PE is the 3rd most common cause of CV death
- PE is classified by risk:
  - High risk
  - Intermediate-high risk
  - Intermediate-low risk
  - Low risk
- Older classification used massive vs submassive
  - Massive = high risk
  - Submassive = <high risk
- Massive and submassive isn't used anymore because the size of the clot does not dictate treatment

PE Classification

- **Low Risk PE** – hemodynamically stable patient with no RV strain and normal cardiac biomarkers (troponin and BNP)
- **High risk PE** – defined by presence of PE with associated shock (end organ malperfusion), cardiac arrest, or hypotension (SBP <90 mmHg or decrease in SBP >40 mmHg for >15 minutes)
- **Intermediate risk PE** – No high risk features (see above) but there is evidence of RV strain and/or abnormal cardiac biomarkers
  - **Intermediate-High risk PE**: RV strain AND elevated biomarkers
  - **Intermediate-Low risk PE**: RV strain OR elevated biomarkers

PE Management

- There are numerous management options for PE ranging from anticoagulation alone to full cardiopulmonary support
- It can be challenging to match the level of support or treatments needed to the patient
- The goal is to accurately identify the risk of the PE and match that risk to the appropriate therapy
- Many hospital systems (including UK) have adopted Pulmonary Embolism Response Team to expedite risk stratification and management of PE

UK PERT Algorithm

UK PE Protocol: Link



PE Management

- All patients – treat with anticoagulation and assess bleeding risk
- Low Risk PE – generally treated with anticoagulation alone.
  - Often can be managed as an outpatient
- High Risk PE – requires urgent, aggressive management
  - At UK, we typically opt for ECMO support as first line for these patients
  - If not an ECMO candidate, consider systemic thrombolytic therapy (assess for contraindications!!)

Table 2.

Absolute contraindications to thrombolysis therapy for confirmed PE:

- Active internal bleeding
- Bleeding diathesis
- History of recent stroke (within three months)
- Presence of intracranial conditions that may increase the risk of bleeding (e.g. some neopla
- Recent intracranial or intraspinal surgery or serious head trauma (within 3 months)
- Suspected aortic dissection

Relative contraindications to thrombolysis therapy for confirmed PE:

- History of chronic, severe, poorly controlled hypertension
- Current severe uncontrolled hypertension (SBP >180 mmHg or DBP >110 mmHg)
- History of ischemic stroke more than three months prior
- Traumatic or prolonged (>10 minute) CPR or major surgery less than three weeks
- Recent internal bleeding (within two to four weeks)
- Noncompressible vascular punctures
- Pregnancy
- Active peptic ulcer
- Pericarditis or pericardial fluid
- Current use of anticoagulant (eg, warfarin sodium) that has produced an elevated INR >1.7
- Age >75 years

Intermediate risk PE

- Significant heterogeneity in this population with wide range of prognosis (hence the sub categories or intermediate-high and –low)
- Numerous treatment options exist but little evidence to back up one treatment approach vs the others
- Generally, the intermediate-low risk PE are managed with anticoagulation alone
- Intermediate-high risk patients are managed as a case-by-case assessment with significant variation between institutions and individual providers

Intermediate Risk PE Treatments

Anticoagulation alone

AC alone with close monitoring for treatment response; may need escalation of therapy for worsening hemodynamics

Catheter-directed thrombolysis



Catheter are placed into the R and L pulmonary arteries via the femoral veins. Lytics are locally delivered and thrombolysis is enhanced by ultrasonic waves that are purported to enhance clot breakdown

Mechanical Thrombectomy



Clots are manually extracted from the proximal pulmonary arteries

Inpatient PE Management

- All patients (regardless of PE risk) and treatment strategy require anticoagulation and careful monitoring for bleeding complications
- Determine if PE is provoked or unprovoked to help guide longterm anticoagulation management
- Recommend bedrest for the first 24 to 48 hours at least
- Monitor for bleeding
- Consider work up for antiphospholipid antibodies since these patients require warfarin anticoagulation (generally all other PE's are managed with DOACs)
- If patients have RV dysfunction on arrival, they will need a repeat limited echo in the outpatient setting


VT Storm

Electrical Storm

- Defined as 3 or more ventricular arrhythmia episodes within 24 hours
- Storm (or ventricular arrhythmias require an arrhythmic substrate and a proarrhythmic trigger
- Management consists of:
  - Stabilization
  - Identification and treatment of trigger(s)
  - Escalation of treatments to quiet the storm

FIGURE 1 Mechanisms of Arrhythmogenesis in Electrical Storm



Electrical Storm

- Commonly, the substrate is ischemic cardiomyopathy with scar in the ventricle (with or without active ischemia)
- Within a scar in the ventricle, there are small channels of myocardium that can conduct a depolarization
- If a channel leads to a self- perpetuating circuit (re-entry), the myocardium will be continually depolarized from the ventricle.





TABLE 1 Structural and Electrical Substrates Predisposing to Electrical Storm, With Associated Disease-Targeted Therapies[1,2]

Substrate	Triggers for ES	Disease-Targeted Therapy
Structural heart disease		
ICM	Acute ischemia Sympathetic tone Decompensated HF	Revascularization if indicated Catheter ablation
NICM	Sympathetic tone Decompensated HF	Hemodynamic support Consider catheter ablation
Arrhythmogenic cardiomyopathy	Sympathetic tone	Catheter ablation
Cardiac sarcoidosis	Granulomatous inflammation Initiation of immune suppression (occasionally)	Immune suppression if active inflammation Catheter ablation
Chagas disease	Inflammation	Antitrypanosomal therapy for active infection Autonomic modulation Catheter ablation
Viral or lymphocytic myocarditis	Inflammation	Immune suppressive therapy for selected patients Hemodynamic support
Giant cell myocarditis	Inflammation	Immune suppressive therapy Hemodynamic support
Conduction defects (channelopathies)		
Congenital long QT syndrome	QT-prolonging agents Sympathetic tone	Avoid QT-prolonging agents Beta-blockers Atrial pacing Autonomic modulation
Acquired long QT syndrome	QT-prolonging agents Bradycardia	Avoid QT-prolonging agents IV magnesium Atrial pacing Isoproterenol
CPVT	Sympathetic tone ICD shocks	Beta-blockers Flecainide Autonomic modulation
Brugada syndrome	Parasympathetic tone Fever Excessive alcohol intake	Avoid sodium channel blockers Avoid provoking drugs/conditions Isoproterenol or quinidine Consider catheter ablation
Early repolarization syndrome or idiopathic VF	Parasympathetic tone	Isoproterenol or quinidine Consider catheter ablation for PVC triggers
Short QT syndrome	Parasympathetic tone	Isoproterenol or quinidine
Idiopathic or short-coupled VF	Parasympathetic tone	IV verapamil Isoproterenol or quinidine Consider catheter ablation for PVC triggers
Idiopathic (outflow tract) VT	Sympathetic tone	Beta-blockers or verapamil

CCU monitoring for VT Storm

FIGURE 3 Diagnostic and Clinical Assessment for Patients With Electrical Storm

Swan-Ganz Catheter
- PCWP
- Mean PA pressure
- Mean RA pressure
- Mixed venous hemoglobin saturation

Coronary Angiography
- Define the presence, anatomy, and severity of coronary artery disease



Chest X-ray
- Signs of congestion?
  - cardiomegaly, pleural effusions, pulmonary edema, etc
- Extracardiac devices?
  - LVAD or ICD



12-lead ECG
- WCTs captured on ECG
  - VT vs SVT?
  - Rate and morphologic characteristics of VA
- Baseline ECG
  - Comparison to VA
  - Ischemia?
  - QT interval prolongation?

Device Interrogation
- VA burden and characteristics
- Frequency and effectiveness of device therapies
- Device therapy appropriateness



History & Physical
- Cardiac symptoms?
  - Fatigue, dyspnea, palpitations, orthopnea, weight gain, anginal symptoms, syncope, device shocks, etc
- Evident precipitants?
  - Fever, illicit drug use, medication discontinuation, etc
- Physical exam abnormalities?
  - Elevated JVP, pulmonary rales, peripheral edema, cool extremities, skin mottling, slow capillary refill, etc

POCUS
- Biventricular systolic function
- Diastology and estimation of ventricular filling pressures
- Estimation of cardiac output
- Coexisting valvular heart disease?
- Sonographic B-lines?

Vital Signs
- Heart rate
- Blood pressure
- Respiratory rate
- O_2 saturation
- Temperature
- Urinary output

Labs
- ABG
- Serum lactate
- Cardiac troponin
- NT-proBNP
- Mg^{2+}, K^+, HCO_3^-
- Renal function indices (eg, serum creatinine)
- Drug levels (eg, digoxin or illicit drugs)

Management of VT Storm



CCU tenets of management:

- Antiarrhythmic Drugs
- Antiadrenergic therapy
- Sedation/Anxiolysis
- Hemodynamic Support

Treatment Escalation

Intensity	Antiarrhythmic Drugs	Adrenergic Blockade	Sedation/Anxiolysis	Hemodynamic Support
Step 1	**Amiodarone IV*** • Bolus 300 mg (max 5 mg/kg) over 20 min • Repeat 150 mg bolus over 10 min for recurrent VA • Infusion 1 mg/min until free from VA ≥6 hours (may continue for longer) • Continue 0.5 mg/min until ES resolves	**Oral beta-blocker** • Propranolol 20-40 mg Q6h (preferred) • Metoprolol tartrate 25-50 mg Q6h (may be less effective) • May instead increase GDMT beta-blocker (eg, bisoprolol, carvedilol, metoprolol succinate) for selected low-risk patients	**Benzodiazepine** • Lorazepam 1 mg Q4-6h PRN • Diazepam 5 mg Q4-6h PRN • Midazolam 2 mg Q1-2h PRN	**Vasopressors** • Phenylephrine 0.1-2.0 µg/kg/min • Vasopressin 0.01-0.04 U/min • Norepinephrine 0.02-0.2 µg/kg/min

Step 2	**Lidocaine IV†**
	• Bolus 1-1.5 mg/kg (max 100-120 mg)
	• May repeat 0.5-0.75 mg/kg Q5-10 min x1-2 doses (max 300 mg or 3 mg/kg)
	• Infusion 1-2 mg/min (max 4 mg/min)
	• Goal serum procainamide concentration:
	  • 1.5-5 µg/mL
		IV beta-blocker
		• Esmolol
		  • Bolus 0.5 mg/kg (may repeat Q5 min x2)
		  • Infusion 50-300 µg/kg/min
		• Propranolol 1-3 mg Q5 min (max 5 mg)
		• Metoprolol 2.5-5 mg Q5 min (max 15 mg)
			Dexmedetomidine
			• Bolus (optional) 0.5-1 µg/kg over 10 min (typically not recommended due to risk of hypotension)
			• Infusion 0.2-0.7 µg/kg/h (maximum 1.0-1.5 µg/kg/h)
				Intra-aortic balloon pump
				• Contraindicated with aortic aneurysm/dissection, severe aortic insufficiency, or peripheral vascular disease
				• Less effective with tachycardia or atrial fibrillation

Step 3	**Procainamide IV†**
	• Bolus 10-15 mg/kg (max 17-20 mg/kg, usually 1 g total) over 30-60 min
	• Infusion 1-2 mg/min (max 4 mg/min)
	• Goal serum procainamide concentration:
	  • 4-8 µg/mL (up to 10 µg/mL)
		Stellate ganglion blockade
		• Left stellate ganglion blockade
		  • 20 mL of 0.25% bupivacaine without epinephrine
		• Bilateral blocks if intubated
			General anesthesia
			• Endotracheal intubation
			• Propofol infusion often used, titrated to RASS goal of −3
			• Opioid typically added (eg, fentanyl infusion)
				Advanced MCS
				• ECMO preferred
				• Percutaneous LVAD can be considered for selected patients
				• Contraindicated with severe aortic insufficiency or peripheral vascular disease

Treatment Escalation



Guideline Recommendations

TABLE 2 ESC Guideline Recommendations for Electrical Storm[2]

Class I Recommendations
Mild to moderate sedation is recommended in patients with ES to alleviate psychological distress and reduce sympathetic tone (LOE: C)
Antiarrhythmic therapy with beta-blockers (nonselective preferred) in combination with intravenous amiodarone is recommended in patients with structural heart disease and ES unless contraindicated (LOE: B)
IV magnesium with supplementation of potassium is recommended in patients with TdP (LOE: C)
Isoproterenol or transvenous pacing to increase heart rate is recommended in patients with acquired long QT syndrome and recurrent TdP despite correction of precipitating conditions and magnesium (LOE: C)
Catheter ablation is recommended in patients presenting with incessant VT or ES caused by MMVT refractory to AADs (LOE: B)
Class IIa Recommendations
Deep sedation/intubation should be considered in patients with an intractable ES refractory to drug treatment (LOE: C)
Catheter ablation should be considered in patients with recurrent episodes of PMVT/VF triggered by a similar PVC, nonresponsive to medical treatment or coronary revascularization (LOE: C)
Class IIb Recommendations
Quinidine may be considered in patients with CAD and ES caused by recurrent PMVT when other AAD therapy fails (LOE: C)
Autonomic modulation may be considered in patients with ES refractory to drug treatment and in whom catheter ablation is ineffective or not possible (LOE: C)
Institution of mechanical circulatory support may be considered in the management of drug-refractory ES and cardiogenic shock (LOE: C)

For more about VT storm, I recommend the 2023 JACC State of the Art Review:

Multidisciplinary Critical Care Management of Electrical Storm: JACC State-of-the-Art Review. J Am Coll Cardiol. 2023 Jun 6;81(22):2189-2206.

https://www.jacc.org/doi/abs/10.1016/j.jacc.2023.03.424

VT Antiarrhythmic Drugs

Amiodarone

- Class III Antiarrhythmic Drug (but actually effects on myocytes extends beyond typical Class III effects with properties of Class Ia, II, and IV agents)
  - Block potassium channels – prolongs repolarization
- First line treatment for VT
- Dosing: 150 mg bolus (given over 10 minutes) following by drip at 1 mg/min x 6 hours, then 0.5 mg/min x 18 hours
  - Full load is 10 g



Amiodarone

- Pharmacology:
  - Distribution: Highly lipophilic with extensive volume of distribution in skeletal muscles and adipose tissue
  - Metabolism: CYP450 enzymes (Hepatic)
  - Elimination: through bile, exceptionally long half life (effects can persist for up to 3 months after discontinuation)
- Side effects: bradycardia, hypotension (mild), prolonged QT; pulmonary fibrosis (usually within first year of use), elevated transaminase levels, thyroid toxicity (hypo>hyperthyroidism), corneal deposits (photophobia, halos, optic neuropathy), neurotoxicity (peripheral neuropathy, ataxia), photosensitivity, blue skin discoloration

Lidocaine

- Class Ib Antiarrhythmic Drug – blocks sodium channels
- 2nd or 3rd line treatment for VT
  - Most effective in ischemic VT (as opposed to scar-mediated)
- Dosing: 1 – 1.5 mg/kg bolus, drip at 1-4 mg/min
- Pharmacology:
  - Rapid onset of action (3-5 minutes)
  - Half life = 1.5 to 2 hours
  - Metabolism: hepatic CYP enzymes
  - Elimination: 90% renal
- Side effects: dizziness, paresthesias, delirium, slurred speech, tinnitus, seizures



Ventricular Action Potential

Class IA: *e.g., quinidine*
- Moderate Na^+-channel blockade
- ↑ ERP

Class IB: *e.g., lodocaine*
- Weak Na^+-channel blockade
- ↓ ERP

Class IC: *e.g., flecainide*
- Strong Na^+-channel blockade
- → ERP

RK '22

Procainamide

- Class Ia Antiarrhythmic Drug – strong Na channel blocker (decreases myocardial excitability, reduces conduction speed)
- Uses: VT, afib, WPW
- Dosing: 6-17 mg/kg at 0.2-0.5 mg/kg/min
- Pharmacology:
  - Onset: 10-30 minutes
  - Metabolism: hepatic enzymes convert drug to active metabolite N-acetyl procainamide (NAPA)
  - Half life: 2.5 to 5 hours



Procainamide

- Side Effects: bradycardia, hypotension, rash (lupus-like), prolongation of QT, QRS, and PR intervals, blood dyscrasias
- Evidence in VT:
  - PROCAMIO Trial – randomized patients presenting with VT to amiodarone or procainamide
  - Procainamide was safer and more effective at VT termination



Summary of Antiarrhythmic Drugs (next 3 slides)

Class	Drug	Mechanism	Use	Dosing	Side effects
IA	Procain-amide	Block Na+ channel; reduce slope phase 0; prolong repol	SVT, VT; WPW w/ AF-RVR; Brugada provocation	**IV:** (L) 6-13 mg/kg @ 0.2-0.5 mg/kg/min; (M) 2-6mg/min **PO:** (L) 500-1000 mg; (M) 250-1000 mg q4-6h	NAPA (metabolite) can cause TdP; rash/fever/myalgia/Raynaud, agranulo-cytosis, SLE-like syndrome, HoTN
	Quinidine		VT/VF in Brugada; short QT	**IV:** (L) 6-10 mg/kg @ 0.3-0.5 mg/kg/min; **PO:** (L): 800-1000 mg; (M): 300-600 q6h	N/v/d, abd pain, anorexia; tinnitus, hearing loss, visual disturbances, psychosis; ITP, hemolytic anemia; CV: hypotension, heart block
	Disopyr-amide		PVCs, VT, AF/AFL	**PO:** 100-300 mg q6-8h	Parasympathetic: urinary retention, constipation, blurred vision, , dry mouth; TdP; negative inotrope
IB	Mexiletine	Block Na+ channel; shortens the APD	VT	**PO**: (L) 400-600 mg; (M): 150-300 mg q8-12h	Tremor, dysarthria, dizziness, paresthesia, diplopia, nystagmus, confusion, n/v, hypotension
	Phenytoin		Tachyarrhythmias from dig toxicity	**IV:** (L) 100 mg q5m for ≤1g **PO:** (L) 1000 mg; (M) 100-400 q12-24h	Nystagmus/ataxia, drowsiness/coma, nausea/anorexia, gingival hypertrophy megalo. anemia, PN, DI Lupus
	Lidocaine		VT (less for mVT)	**IV:** (L) 1-3 mg/kg @ 20-50 mg/min; (M) 1-4 mg/min	Dizziness, paresthesias, confusion, delirium, coma, seizures
IC	Flecainide	Block Na+ channel; reduce slope phase 0	VT, pAF, AT, AFL; provocative for Brugada	**PO:** 50-200 mg q12h	Confusion, irritability; negative inotrope, caution in SSS, CI in structural or ischemic heart disease
	Propaf-enone		VT, pAF	**PO:** (L) 600-900 mg; (M) 150-300 q8-12h	Dizziness, taste disturb, blurry vision, GI, brochospastic lung exacerbation, AV block, worsening HF, CI in IHD

Class	Drug	Mechanism	Use	Dosing	Side effects
II	Esmolol	β1 antag. (t-½ = 9 min	AF, AFL, SVT, prolonged QT, AT from digoxin toxicity; ischemic heart disease; arrhythmias d/t thyrotox., pheochromocytoma, exercise, emotion, cocaine	**IV:** (L) 20-30 mg (500 mcg/kg) x 1 min; (M) 2-21 mg/min (25-300 mcg/kg/min)	Hypotension, bradycardia, CHF, worsening angina upon withdrawal (propranolol), worsening asthma or COPD, mental depression, hypoglycemia in diabetics, vivid dreams or insomnia, impaired sexual function; less side effects with β1 selective antagonists; propranolol crosses the blood brain barrier and can cause AMS
	Atenolol	β1 antag. (Atenolol ↑ potency c/t metoprolol)		**IV:** 5 mg over 5 min, repeat after 10 min	
	Metoprolol			**IV:** (L) 2.5-5 mg q2-5min to max 15 mg **PO:** BID (tartrate)/QD (succinate):max 400 mg/d	
	Propanolol	Non-selective β-blocker		**IV:** 0.25-0.5 mg q5m to $\leq$ 0.20 mg/kg **PO:** 10-200 mg q6-8h	
	Nadolol			**PO:** 20-40 mg/day	
	Labetalol	Mixed non-selective: β1, β2, α1 blocker		**IV:** (L) 20-80 mg over 1-2 min → 20-80 mg q10m *or* 0.5-2 mg/min **PO:** 100 mg q8-12h up to 2400 mg/day	
	Carvedilol			**PO:** 3.125-25 mg BID; >85 kg: max 50 mg BID	
III	Sotalol	Block potassium channels; prolong repol; amio has properties of class Ia, II, and IV agents	VT and AF, SVTs	**PO:** 80-320 mg q12h	QT prolongation; TdP
	Amio-darone		Atrial and ventricular arrhythmias	**IV:** (L) 150 mg over 10 min → 1 mg/min x 6 hours → 0.5 mg/min x 18 hr; (M) 0.5 mg/min **PO:** (L) 1.2-1.8 g QD for 7-10g; rebolus 150 mg prn up to daily max 2.1 g; (M) 100-600 mg QD	Hypotension (IV form), bradycardia, prolonged QT, lung/liver/thyroid toxicity
	Drone-darone		AF, AFL for maintenance of SR	**PO:** 400 mg q12h	Rash, photosensitivity, n/d, h/a; CI in HF, permanent AF, severe liver dz
	Ibutilide		Acute termination of AF, AFL	**IV:** 1 mg over 10 min	QT prolongation (1.7%), TdP, h/a (3.6%)
	Dofetilide		Acute term/ chronic AF/AFL suppress	**PO:** 0.125-0.5 mg q12h	QT prolongation, TdP

Class	Drug	Mechanism	Use	Dosing	Side effects
IV	Verapamil	Ca^{++} channel blocker; slows AVN conduct. and phase 2 of cardiac AP	AF AFL, SVT HTN, angina	**IV:** (L) 5-10 mg over 1-2 min; (M) 0.005 mg/kg/min **PO:** 30-120 mg q6-8h	Bradycardia, high degree AV block, hypotension, pulmonary edema (in HF)
	Diltiazem			**IV:** (L) 0.25 mg/kg over 2 min, repeat; (M) 5-15 mg/h **PO:** 30-120 mg q6h	
Other	Adenosine	Slows AVN conduct.; interrupts AVN re-entry circuits	pSVT	**IV:** 6 mg over 1-2 sec f/b NS flush; 12 mg bolus max 2 doses after 1-2 min (1/2 dose for CVC admin)	AVB, asystole, VT/VF (put pads on first), bronchospasm, seizure flushing, SOA
	Digoxin	↓ AVN conduct., ↑ vagal activity, + inotrope	AF, pSVT, HF	**PO/IV:** (L) 250-500 mg to 1.5 g load in 24 hr; check level 6-12 hr after last dose; (M) 250-500 mg QOD/QD	Caution in renal disease; Levels: 0.5-0.9 in HF, 0.5-2.0 in AF; ST depression, junctional tachycardia with variable block, n/v, blurry vision

Symptomatic Bradycardia
"A Case of the Slows"



Symptomatic Bradycardia Rhythms

- Sinus rhythm with AV block – usually 2nd degree Mobitz type II or 3rd degree (complete heart block)
- Atrial Fibrillation with slow ventricular response (SVR)
- Usually not sinus bradycardia

Mobitz type II



- Look for dropped p waves (no QRS following)
- PR interval is <u>constant</u>
- In Mobitz type I (Wenckebach) there will be preceding PR segment prolongation, varying PR interval
- R-R interval is <u>irregular</u>
- In complete heart block, the R-R interval is constant

Complete Heart Block



- There is no relationship between the p waves and the QRS complexes
- The P-P interval is constant
- The R-R interval is constant
- The PR interval is variable

Symptomatic Bradycardia Management

- Determine hemodynamic stability
  - Hypotensive?
  - Symptomatic?
  - Perfusing (assess lactate, creatinine, urine output, etc.)
- Stabilize if unstable
- Look for reversible causes (see next slides)

Symptomatic Bradycardia Causes

- Senile degeneration of conduction system (most common)
- Medications:
  - Beta blockers
  - Nondihydropyridine CCBs
  - Antiarrhythmic drugs
- Iatrogenic (cardiac surgery, TAVR, etc.)
- Infiltrative cardiomyopathies (amyloid, sarcoid)
- Severe electrolyte or metabolic derangements
- Myocardial Ischemia
- Endocarditis (especially aortic root abscess)
- Lyme Disease (rare cause in KY)

Triage and Management

- Pads on chest, continuous tele, strict bedrest
- Quickly assess for ischemia and major electrolyte abnormalities
- If unstable, patients will need pacing
  - Transcutaneous (ouch!)
  - Temporary transvenous pacemaker (TVP)
- Can try to manage with chronotropic vasoactive agents:
  - Isuprel (isoprotenol)
  - Dopamine
  - Anything with B1 activity (epi, norepi, etc.)

Temporary transvenous pacemaker (TVP)



- Used to stabilize a patient until a permanent pacemaker is inserted or patient recovers rhythm (in cases with a reversible cause)
- Requires a central line introducer through which the pacing wire can be inserted
- The pacing wire has a balloon tip that should be positioning in the RV apex to pace the ventricles
- The wires connects to a box (shown left) to program pacing parameters

Temporary transvenous pacemaker (TVP)



- Central line introducer placed under US guidance (just like any central line)
- Pacing wire is positioned with bedside echo, fluoro (in the cath lab), and/or by observing paced rhythm on the monitor
- Get a CXR after placement to check position and rule out complications (PTX, pericardial effusion, etc.)
- Patients need to be on bedrest with a TVP to prevent pacing wire from moving
- TVP threshold (lowest output required to capture the ventricle with pacing) should be checked at least daily

Pacing Basics

- Pacemaker mode donated by 4 codes:
  - Chamber(s) paced
  - Chamber(s) sensed
  - Response to sensing
  - Rate modulation (yes/no)

I Chamber Paced	II Chamber Sensed	III Response to Sensing	IV Rate Modulation
V: Ventricle	V: Ventricle	T: Triggered	R: Rate modulating
A: Atrium	A: Atrium	I: Inhibited	O: None
D: Dual (A+V)	D: Dual (A+V)	D: Dual (T+I)	
O: None	O: None	O: None	

- Common Modes
  - VVIR – ventricular demand pacing
  - AAIR – atrial demand pacing, for patients with sinus node dysfunction
  - DDDR – used with AVN dysfunction
  - VOO/DOO – asynchronous pacing (program for MRI or during surgical procedures)

Pacemaker Problems

- Failure to capture – device is not pacing when it should
  - Pacer spikes present without corresponding waveform (no P wave or QRS following)
  - Causes: Output setting problem, resistance to conduction, dislodged or fractured lead, refractory tissue
- Failure to sense – device is pacing when it shouldn't
  - Pacer does not detect intrinsic beats and initiates an impulse (spike EKG) inappropriately. This "extra" impulse may or may not capture
  - Causes: Sensing setting problem, battery depletion, fusion beat, dislodged or fractured lead
- Oversensing – device is not pacing when it should
  - Pacer is inhibited by events that should be ignored
  - Causes: sensing setting problem, electromagnetic interference (electrocautery during surgery), T waves (mistaken for a QRS complex), dislodged or fractured lead

Pacemaker Problems

- Failure to capture



Pacer impulses with no myocardial activity following

- Failure to sense



Pacer should not deliver an impulse here because there is a native QRS beat

- Oversensing



Pacer sees this activity and thinks the heart is intrinsically pacing, so it doesn't deliver an impulse